A study showed that serum collagen biomarkers were dysregulated in cutaneous psoriasis (PsC), an important finding considering that collagens are involved in both PsC and psoriatic arthritis (PsA). The findings were reported in Clinical and Experimental Rheumatology.
In this study, researchers assessed 41 healthy donors, 30 patients with PsC, and 30 patients with PsA. Collagen biomarkers were discerned using ELISA immunoassays. According to the results, patients with PsC and PsA had lower levels of collagen PRO-C1 and C3M compared with the control arm, while collagen C2M was elevated in patients with PsA and PsC compared with the control group. Moreover, the researchers observed that C1M measures were able to discern between PsC and PsA and may be a viable biomarker of bone involvement. Overall, the researchers concluded that collagen C1M is a possible biomarker for inflammation in PsC and PsA.
Reference: Holm Nielsen S, Magee C, Groen SS, et al. Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers [published online ahead of print, 2022 Jul 28]. Clin Exp Rheumatol. 2022;10.55563/clinexprheumatol/jmt9jv. doi:10.55563/clinexprheumatol/jmt9jv
